Kardigan, Inc.
KARD
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.88B
Close$
$1.59
92.4% downside
Current Fair Value
92.4% downsideOvervalued by 92.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.88 Billion |
|---|---|
| Enterprise Value | $1.51 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.2 |
| Beta | 0 |
| Outstanding Shares | 93,467,940 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -9.82 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 3.49 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.68
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 61.21%▲ 61.21% |
|---|---|
| Total Invested | $1.37B |
| Investors Holding | 69▲ 69.00% |
ESG Score
No data
About Kardigan, Inc.
241 employees
CEO: Tassos Gianakakos Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug p...